Kinaset Therapeutics
Medfield, US · Founded 2020 · Delaware corporation · 17 employees on LinkedIn · 11 known investors
Kinaset Therapeutics is a drug developer working on KN-002, a therapeutic candidate for treating severe asthma across patients regardless of the underlying cause of inflammation. The company is advancing toward clinical trials.
Founders & leadership
Kinaset Therapeutics was founded in 2020 by Roger Heerman, Frazer Morgan, and Robert Clarke.
RH
Roger HeermanChief Business/Operating Officer / Co-Founder
FM
Frazer MorganChief Development Officer / Co-Founder
RC
Robert ClarkeChief Executive Officer / Board Member / Co-Founder
CO
Christopher O’BrienChief Medical Officer
Board
TK
Tom KingDirector of the Issuer
KB
BV
Bram VanparysDirector of the Issuer
Investors · 11
5AM Ventures✓ verifiedBoston · $100K – $4M
Atlas Venture✓ verifiedCambridge · $500K – $1M
RA Capital✓ verifiedBoston
EQT Life Sciences✓ verifiedLuxembourg · $11M – $66M
Sixty Degree CapitalNorth York
Vivo CapitalPalo Alto · $10M – $50M
GimvreportedAntwerp · $21M – $430M
Willett AdvisorsreportedNew York
Also in the syndicate · 3
Forge Life Science PartnersleadPictet Alternative AdvisorsSchroders Capital
Funding
SEC filings, press & company announcements$133M disclosed across 3 rounds · 2020–2026
- $103MSeries BJan 2026 · 3 sources
Forge Life Science Partners (lead), RA Capital Management (lead), 5AM Ventures, Atlas Venture, EQT Life Sciences, Gimv, Pictet Alternative Advisors, Schroders Capital, Sixty Degree Capital, Vivo Capital, Willett Advisors
Source ↗
▶$28.5MraisedJul 2023 · 3 investors · PharmaceuticalsRule 506(b)
▶$28.5MraisedJul 2023 · 3 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Tom KingDirector
- Jamil BegDirector
- Robert ClarkeExecutive Officer, Director, Promoter
- Bram VanparysDirector
- Frazer MorganExecutive Officer, Promoter
- Kevin BittermanDirector
- Roger HeermanExecutive Officer, Promoter
- Offering amount
- $41M
- Amount sold
- $28.5M
- Minimum investment
- $7.1M
- First sale
- Jul 2022
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
▶$1.5MraisedAug 2020 · 3 investors · PharmaceuticalsRule 506(b)
▶$1.5MraisedAug 2020 · 3 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Jamil BegDirector
- Tom KingDirector
- Roger HeermanExecutive Officer, Promoter
- Kevin BittermanDirector
- Frazer MorganExecutive Officer, Promoter
- Bram VanparysDirector
- Robert ClarkeExecutive Officer, Director, Promoter
- Offering amount
- $40M
- Amount sold
- $1.5M
- Minimum investment
- $375K
- First sale
- Jul 2020
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Founder mafia
2 people who came through Kinaset Therapeutics went on to found or lead other companies.
Competitors · 5
by search overlapKite Pharma14 shared keywordsKite Pharma develops CAR T-cell therapies for cancer patients, engineering the immune system's cells to target and attack cancer. Each therapy is individualized per patient through a multi-step manufacturing process.
Crinetics10 shared keywordsCrinetics is a pharmaceutical company focused on discovering, developing, and commercializing therapies for endocrine diseases and endocrine-related conditions.
Kyverna Therapeutics9 shared keywordsKyverna is a clinical-stage biopharmaceutical company developing CAR T-cell therapies to treat autoimmune diseases through B cell depletion and immune system reset. The company conducts clinical trials for multiple autoimmune conditions globally.
Kiniksa8 shared keywordsKiniksa is a global biopharmaceutical company that discovers and develops novel therapies for patients with unmet medical needs, with a focus on cardiovascular diseases and related conditions. The company has an FDA-approved therapy and multiple clinical-stage assets in its pipeline.
Kenaitx7 shared keywordsKenai Therapeutics is a clinical-stage biotechnology company developing off-the-shelf dopamine neuron replacement cell therapies and gene-modified medicines for neurological conditions such as Parkinson's disease. Its lead program, RNDP-001, is being evaluated in the REPLACE Phase 1b/2a clinical trial for idiopathic Parkinson's disease.
Companies competing with Kinaset Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Kinaset Therapeutics do?
- Kinaset Therapeutics is a drug developer working on KN-002, a therapeutic candidate for treating severe asthma across patients regardless of the underlying cause of inflammation. The company is advancing toward clinical trials.
- Who founded Kinaset Therapeutics?
- Kinaset Therapeutics was founded by Roger Heerman, Frazer Morgan, Robert Clarke in 2020.
- Who are Kinaset Therapeutics's investors?
- Kinaset Therapeutics's investors include 5AM Ventures, Atlas Venture, RA Capital, EQT Life Sciences, Sixty Degree Capital, Vivo Capital, Gimv, Willett Advisors.
- How much funding has Kinaset Therapeutics raised?
- Kinaset Therapeutics has disclosed $133M raised across 3 rounds.
- Where is Kinaset Therapeutics headquartered?
- Kinaset Therapeutics is headquartered in Medfield, US.